Research Article

Development and Validation of a 34-Gene Inherited Cancer Predisposition Panel Using Next-Generation Sequencing

Sun Hee Rosenthal,¹ Weimin Sun,¹ Ke Zhang,¹ Yan Liu,¹ Quoclinh Nguyen,¹ Anna Gerasimova,¹ Camille Nery,¹ Linda Cheng,¹ Carolyn Castonguay,¹ Elaine Hiller,¹ James Li,¹ Christopher Elzinga,² David Wolfson,³ Alla Smolgovsky,¹ Rebecca Chen,¹ Arlene Buller-Burckle,¹ Joseph Catanese,¹ Andrew Grupe,¹ Felicitas Lacbawan,¹ and Renius Owen ¹

¹Department of Genetics, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92675, USA
²Athena/Quest Diagnostics, Marlborough, MA 01752, USA

Correspondence should be addressed to Renius Owen; renius.x.owen@questdiagnostics.com

Received 27 March 2019; Accepted 4 August 2019; Published 23 January 2020

Academic Editor: Kui Li

Copyright © 2020 Sun Hee Rosenthal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The use of genetic testing to identify individuals with hereditary cancer syndromes has been widely adopted by clinicians for management of inherited cancer risk. The objective of this study was to develop and validate a 34-gene inherited cancer predisposition panel using targeted capture-based next-generation sequencing (NGS). The panel incorporates genes underlying well-characterized cancer syndromes, such as BRCA1 and BRCA2 (BRCA1/2), along with more recently discovered genes associated with increased cancer risk. We performed a validation study on 133 unique specimens, including 33 with known variant status; known variants included single nucleotide variants (SNVs) and small insertions and deletions (Indels), as well as copy-number variants (CNVs). The analytical validation study achieved 100% sensitivity and specificity for SNVs and small Indels, with 100% sensitivity and 98.0% specificity for CNVs using in-house developed CNV flagging algorithm. We employed a microarray comparative genomic hybridization (aCGH) method for all specimens that the algorithm flags as CNV-positive for confirmation. In combination with aCGH confirmation, CNV detection specificity improved to 100%. We additionally report results of the first 500 consecutive specimens submitted for clinical testing with the 34-gene panel, identifying 53 deleterious variants in 13 genes in 49 individuals. Half of the detected pathogenic/likely pathogenic variants were found in BRCA1 (23%), BRCA2 (23%), or the Lynch syndrome-associated genes PM2 (4%) and MLH1 (2%). The other half were detected in 9 other genes: MUTYH (17%), CHEK2 (15%), ATM (4%), PALB2 (4%), BARD1 (2%), CDH1 (2%), CDKN2A (2%), RAD51C (2%), and RET (2%). Our validation studies and initial clinical data demonstrate that a 34-gene inherited cancer predisposition panel can provide clinically significant information for cancer risk assessment.

1. Introduction

It is important to identify individuals with hereditary cancer efficiently and in a cost-effective manner, as they account for 5–10% of all cancers [1]. Over the last few years, rapid advances in next-generation sequencing (NGS) technologies have allowed simultaneous interrogation of multiple genes. NGS technologies perform at higher throughput than Sanger sequencing, since they work in a massively parallel manner [2]. As a result, multigene panel tests utilizing NGS can be a cost-effective and efficient way to detect clinically actionable mutations in appropriately selected patients [3]. Their use may increase detection of pathogenic mutations compared to single-gene testing [4].

Identifying hereditary cancer susceptibility in an individual with a personal and/or family history can be complex. Pathogenic/likely pathogenic variants in multiple genes can be associated with cancer in a specific organ. For example, ovarian cancer is associated with pathogenic/likely pathogenic variants in multiple genes such as BRCA1, BRCA2, MLH1,
MSH2, RAD51C, and RAD51D [5–11]. On the other hand, pathogenic/likely pathogenic variants in a single gene can increase the risk of more than 1 type of cancer. Women with Lynch syndrome due to MLH1 pathogenic variants have an increased risk of specific cancers, including cancer of the colon or rectum (52–82%), uterus (25–60%), ovary (4–24%), stomach, urinary tract, pancreas, small bowel, hepatobiliary tract, and brain [7–9, 12–19].

Several professional societies have published guidelines that support and define genetic testing for hereditary cancer syndromes. These societies acknowledge that multigene panel testing may benefit individuals when their histories are consistent with multiple possible hereditary cancer syndromes or when a syndrome can be caused by multiple genes [20, 21]. These panels are also informative for families with a limited structure, when family history information is limited, and when the history of cancer is strong but targeted testing has been negative [18, 22–27]. Guidelines, however, do not currently provide guidance on when multigene panel testing may provide actionable additional information for individuals whose histories do not meet these criteria.

Here, we describe the development and validation of a 34-gene inherited cancer predisposition panel using NGS for single-nucleotide variants (SNVs), insertions and deletions (Indels), and exon-level copy number variants (CNVs). We also studied variant detection yield of the panel by summarizing de-identified results from 500 consecutive patient specimens submitted for clinical testing with the 34-gene panel.

### 2. Materials and Methods

#### 2.1. Gene Selection

The 34-genes selected for this panel are associated with well characterized cancer syndromes, along with more recently discovered genes associated with increased cancer risk (Table 1). The genes selected increase the lifetime risk of cancer of the breast, ovary, colon, rectum, endometrium, pancreas, prostate, neuroendocrine system, and/or other cancer types. Genes were selected that conferred at least a twofold increased risk of cancer or a 5% lifetime risk to develop cancer. Additionally, at the time of test development, genetic testing and/or medical management guidelines existed for many of the individual genes on the panel [18, 24–26, 28]. Common polymorphism contributions to a polygenic risk score were excluded from this panel design.

#### 2.2. DNA Specimens

For validation of the 34-gene hereditary cancer predisposition panel, 131 de-identified residual whole blood patient specimens submitted for routine clinical testing were used. In addition, a specimen positive for a 40-base deletion in BRCA1 (GM14094) and the well-characterized NA12878 DNA specimen were tested (Coriell Mutant Cell Repository, Camden, NJ).

To assess variant detection yield of the 34-gene panel in practice, we analyzed findings from the first 500 clinical specimens submitted for testing with this assay. For each patient, informed consent for genetic analysis was obtained. Patient results were de-identified before analysis.

#### 2.3. Next Generation Sequencing

Genomic DNA from whole blood or cultured cells was isolated using the Roche Magnapure system (Roche Molecular Systems, Indianapolis, IN). Isolated genomic DNA was mechanically sheared to an average size of approximately 500 bp using a Covaris instrument LE220 (Covaris Inc., Woburn, MA). The fragmented DNA was enzymatically repaired and end-modified with adenosine (NEBNext Ultra DNA Library prep kit, NEB, Ipswich, MA) to make it receptive to T/A ligation with barcoded adapters (Integrated DNA Technologies, Coral, IL). The ligated products were size-selected (AMPure Beads, Agencourt, Beverly, MA) and amplified (GeneRead DNA 1 Amp Kit, Qiagen, Mississauga, ON) and then the regions of interest were captured using biotinylated RNA baits (SureSelect, Agilent, Mississauga, ON). The baits were designed to capture all coding exons and exon/intron boundaries of the 34 hereditary cancer related genes.

### Table 1: Genes included in the 34-gene inherited cancer predisposition panel.

| Gene name | Coding reference | Genomic reference |
|-----------|------------------|------------------|
| APC       | NM_000038.5      | NG_008481.4      |
| ATM       | NM_00051.3       | NG_009830.1      |
| BARD1     | NM_000465.3      | NG_012047.3      |
| BMP1A     | NM_004329.2      | NG_009362.1      |
| BRCA1     | NM_007294.3      | NG_005905.2      |
| BRCA2     | NM_000059.3      | NG_012772.3      |
| BRIP1     | NM_032043.2      | NG_007409.2      |
| CDH1      | NM_004360.3      | NG_008021.1      |
| CDK4      | NM_00075.3       | NG_007484.2      |
| CDKN2A    | NM_000774        | NG_007485.1      |
| CHEK2     | NM_007194.3      | NG_008150.2      |
| EPCAM     | NM_028354.2      | NG_012352.2      |
| MEN1      | NM_130799.2      | NG_008929.1      |
| MLH1      | NM_000249.3      | NG_007109.2      |
| MSH2      | NM_000252.1      | NG_007110.2      |
| MSH6      | NM_000179.2      | NG_007111.1      |
| MUTHY     | NM_00128425.1    | NG_008189.1      |
| NBN       | NM_002485.4      | NG_008860.1      |
| NF1       | NM_000267.3      | NG_009018.1      |
| PALB2     | NM_024675.3      | NG_007406.1      |
| PMS2      | NM_000535.5      | NG_008466.1      |
| POLD1     | NM_002691.3      | NG_033800.1      |
| POLE      | NM_006231.3      | NG_033840.1      |
| PTEN      | NM_000314.4      | NG_007466.2      |
| RAD51C    | NM_058216.2      | NG_023199.1      |
| RAD51D    | NM_002878.3      | NG_031858.1      |
| RET       | NM_020975.4      | NG_007489.1      |
| SDHB      | NM_003000.2      | NG_012340.1      |
| SDHC      | NM_003001.3      | NG_012767.1      |
| SDHD      | NM_003002.3      | NG_012337.3      |
| SMAD4     | NM_005335.9      | NG_013013.2      |
| STK11     | NM_000455.4      | NG_007460.2      |
| TP53      | NM_000546.5      | NG_017013.2      |
| VHL       | NM_000551.3      | NG_008212.3      |
genes (Table 1). In addition, any noncoding regions of these genes containing currently known pathogenic variants, as well as the promoter regions of APC, MLH1, MSH2, and PTEN were included. The DNA/RNA hybrids were enriched with streptavidin attached magnet beads (Dynabeads MyOne Streptavidin T1, Thermo Fisher Scientific, Markham, ON) and subjected to washing under increasing stringency in order to remove non-targeted DNA sequences. A second amplification was performed (Herculase II Fusion DNA Polymerase, Agilent, Mississauga, ON), followed by bead purification (AMPure Beads, Agencourt, Beverly, MA) to remove all unused primers and nucleotides.

To achieve assay specificity by avoiding interference from pseudogenes, exons 11–15 from PMS2 and CHEK2 were amplified from genomic DNA by long-range PCR (LR–PCR, Takara LA Taq DNA polymerase, Takara Bio, Mountain View, CA). For PMS2 amplification, primers PMS2–LR3F (forward; within exon 10, sequence from Clendenning et al. [29]) and PMS2–LR3Rm (reverse; ~1.6 kb downstream of exon 15) were used. For CHEK2 amplification, primers CHEK2–Fm3 (forward; ~0.6 kb downstream of exon 15) and CHEK2–R (reverse; within intron 10) were used. All primer sequences are listed in Supplemental Table S1. LR–PCR products were subjected to mechanical shearing using a Covaris E220 instrument, enzymatic end repair, and 3′ adenylation, followed by ligation to barcoded adaptors and a second PCR to enrich ligated fragments as described above. Final products from the LR–PCR library and the captured gDNA library were combined and sequenced on an Illumina NextSeq instrument, 2 × 150 cycles (NextSeq500 mid output v2 kit, Illumina, San Diego, CA).

2.4. Bioinformatics Processing. Following the sequencing reaction, sequence alignment and allele assignment were performed. BCL files from NextSeq500 were converted to FASTQ files. The raw sequence reads in FASTQ files were then aligned to the Genome Reference Consortium human genome build 37 (GRCh37), or custom reference genome, using the Burrows–Wheeler Aligner (BWA). The custom reference genome differs from GRCh37 in that highly homologous pseudogene sequences within chr22:16,983,750–16,990,200 and chr7:6,776,750–6,791,250 were replaced with nucleotide T for accurate alignment of LR–PCR library to the CHEK2 and PMS2 gene regions. Mapped reads were filtered by Phred Quality score of read mapping over 30 (>99.9% accuracy), before downstream analysis. Reads were then sorted and indexed using SAMtools, followed by removal of read duplications using Picard Tools. Local realignment and base-quality score recalibration were performed using the Genome Analysis Toolkit (GATK). Average and minimum depth of coverage for every region of interest (ROI) were computed, and variant calling was performed using GATK Unified Genotyper and Haplotyper. A single variant call file (vcf) was created by merging variant call files from both variant callers. Coverage and variant-depth reports were created and loaded to the sequencing database (seqDB). Alamut Batch was used to obtain high-level annotation for detected variants. For EPCAM, only copy number variant analysis was performed. Each targeted base within the ROI (115,483 bp) was required to have at least 20x unique reads.

2.5. Copy Number Variant Analysis. CNV-positive specimens were identified using a CNV flagging algorithm developed in-house based on the well-established NGS read-depth (RD) approach [30, 31]. To calculate the read-depth, we partitioned large targets into nonoverlapping bins of approximately 200 bp and used the average read-depth of each bin. To enhance large CNV signals (e.g. BRCA1 exon 9–12 del, whole gene del.dup), we generated additional target groups by joining multiple bins within the target range. Each target group was considered independently. For CNV target flagging, a normalized target representation value X was calculated using the following steps: (a) target read-depth was divided by mean read-depth of all targets to give relative target read-depth, RDr; (b) principle component analysis (PCA) was performed on the RDr, generating the RDrp; (c) RDrp was further normalized by dividing the target RDrp by the median RDrp of all targets, yielding X. The Z score of each target was calculated from the following formula: $Z = (X - \mu)/\sigma$, where $X$ is normalized RDrp, $\mu$ is the median X across specimens in a batch typically composed of 92 specimens, and $\sigma$ is the median absolute deviation of X from a training set of about 1,300 specimens. To augment the Z score, the Z.adj score was used; the Z.adj score was calculated by dividing the Z score by the standard deviation of Z score across targets, excluding the given target. This Z.adj extracts putative CNV signal from noisy read-depth to discern patterns of read-depth biases. Finally, a CNV target was flagged if the target Z and/or Z.adj for a given target group were over the cut-off value created from a training set of approximately 8,000 specimens. PMS2 and CHEK2 exons 11–15 were excluded from copy number analysis.

2.6. Array Comparative Genomic Hybridization. An aCGH method was used to complement the NGS CNV flagging algorithm. All specimens flagged as having CNVs by NGS were reflexed to aCGH for CNV confirmation. Custom array probes for the 34-genes in the panel were designed using Agilent SureDesign custom design tool. Approximately 57,000 probes were designed, giving on average 26 probes per exon with less density for introns and promoters. Patient specimens and gender-matched reference specimens were labeled with Cy5 and Cy3, respectively, using Agilent SureTag Complete DNA Labeling Kit followed by column purification and volume reduction. The labeled DNA was then combined and hybridized onto a custom microarray slide (Agilent, Mississauga, ON). After hybridization, the slides were washed to remove non-specific binding and then immediately scanned on the Agilent SureScan or C scanner; data were extracted using Agilent CytoGenomics Software. The results were manually reviewed by licensed personnel and a licensed director for report generation.

2.7. Variant Assessment. All variants detected by the NGS panel were manually reviewed by licensed personnel and classified by a team of variant scientists as described previously [32], according to the ACMG guidelines [33]. Classifications were scored as benign, likely benign, unknown significance (VUS), likely pathogenic, or pathogenic. This result was then reviewed by a licensed director for reporting. Variants identified through clinical testing at our laboratory are routinely
submitted to ClinVar [34]. The variant of uncertain significance rate for the first 500 clinical samples was calculated based on the percentage of patients tested with no pathogenic or likely pathogenic variants identified and 1 or more VUSs identified. For this study, variants are considered clinically actionable when classified as either pathogenic or likely pathogenic.

3. Results

3.1. Assay Performance. The 133 unique specimens included in the assay validation study were sequenced for a total of 726 trials in 8 consecutive sequencing runs. We aimed minimum unique sequencing coverage of 50x for 100% of our targeted region of interest. For routine analysis, coverage of 20x is required for all bases in the targeted region. In the validation runs, 99.8% of the targeted regions were covered 100x, with an average median coverage depth of 382x (range: 89–946). All target regions within coding exons were covered over 100x. Among the 726 tested specimens, 99.9% specimens passed coverage requirement of 20x with on average 380x median coverage depth (range: 112–689).

3.2. Technical Validation for SNVs and Indels. Sequencing variant detection accuracy was assessed using 15 specimens with collectively 56 known variants (28 unique) from bidirectional Sanger sequencing in at least one of the following genes: APC, MLH1, MSH2, MSH6, PMS2, and RET. The 28 unique variants included 23 SNVs and 5 deletions. In addition, a BRCA1 c.1175_1214del40 positive specimen GM14094 was tested. All expected 57 variants were accurately detected including the 40 bp deletion in BRCA1 (Table 2). Subsequently, a well-characterized HapMap reference specimen (NA12878) was investigated for the regions with a highly confident published consensus sequence overlapping with our ROI. Out of a total of 91,940 bp tested, all 45 known benign variants were detected, with no false-positive calls (data not shown). All specimens were replicated 9 times, except the BRCA1 c.1175_1214del40 positive control, which repeated 5 times. Collectively, the assay yielded 100% accuracy for detection of known sequencing variants.

To test intra- and inter-assay reproducibility, a set of 30 specimens was analyzed, each in triplicate within a run and repeated three times, for a total of 9 replicates per specimen. The specimens selected for reproducibility studies comprised 15 specimens with known variants used in the accuracy study described above, NA12878, and 14 de-identified specimens with unknown genotype. In all, within reportable ROI, NGS detected 1,733 variants (228 unique) from the 30 specimens. These included 1,708 SNVs (216 unique) and 25 indels (12 unique). Of these, 1,418 variants (179 unique) were in coding exons and 315 variants (49 unique) were in nonexonic regions. It is important to note that there were 4 discordant positions in 115,487 sequenced bases among the 9 trials per specimen. Those positions were residing within homopolymeric regions which are known to cause sequencing artefacts. As all discordant or inconsistent variant calls occurred in nonexonic regions with no known clinical significance, variants observed in those 4 positions were excluded from the reportable range. Within reportable ROI, there were 100% intra- and inter-assay variant call concordances from all 9 trials per specimen.

3.3. Technical Validation for CNVs. To validate the in-house developed CNV flagging algorithm, a set of 103 anonymized DNA specimens with known CNV status were tested for a total of 457 trials. Including the 9 known CNV positives (S1–S9, Table 3). Among the 726 tested specimens, 90 specimens showed concordant CNV calls in at least one of the replicates. All specimens flagged as having CNVs by NGS were reflexed to aCGH for CNV confirmation. All discordant specimens were CNV negative by aCGH. In

| Gene  | Variant              | No. specimen tested |
|-------|----------------------|---------------------|
| APC   | c.1458T>C (p.Tyr486Tyr) | 2                   |
| APC   | c.1635G>A (p.Ala545Ala) | 3                   |
| APC   | c.1958+8T>C (p.?)     | 1                   |
| APC   | c.2547_2550del (p.Asp849Glufs*11) | 1   |
| APC   | c.3468_3470del (p.Glu1157del) | 1   |
| APC   | c.4398del (p.Pro1467Leufs*6) | 1   |
| APC   | c.4479G>A (p.Thr1493Thr) | 3   |
| APC   | c.5034G>A (p.Gly1678Gly) | 3   |
| APC   | c.5268T>G (p.Ser1756Ser) | 3   |
| APC   | c.5465T>A (p.Val1822Asp) | 4   |
| APC   | c.5880G>A (p.Pro1960Pro) | 3   |
| APC   | c.6281del (p.Pro2094Leufs*18) | 1   |
| BRCA1 | c.1175_1214del40 (p.Leu392Glnfs) | 1   |
| MLH1  | c.293G>A (p.Gly98Asp) | 1   |
| MLH1  | c.655A>G (p.Ile219Val) | 1   |
| MSH2  | c.211+9C>G (p.? )   | 1   |
| MSH2  | c.1847C>G (p.Pro616Arg) | 1   |
| MSH2  | c.2647del (p.Ile883Leufs*9) | 1   |
| MSH6  | c.116G>A (p.Gly39Glu) | 1   |
| MSH6  | c.2633T>C (p.Val878Ala) | 1   |
| PMS2  | c.2466T>C (p.Leu822Leu) | 1   |
| PMS2  | c.2007G>A (p.?)     | 3   |
| PMS2  | c.1621A>G (p.Lys541Glu) | 4   |
| PMS2  | c.1408C>T (p.Pro470Ser) | 3   |
| PMS2  | c.780C>G (p.Ser260Ser) | 4   |
| RET   | c.1826G>A (p.Cys609Tyr) | 1   |
| RET   | c.1900T>C (p.Cys634Arg) | 1   |
| RET   | c.2307G>T (p.Leu769Leu) | 5   |
| RET   | c.2372A>T (p.Tyr791Phe) | 1   |
combination with aCGH confirmation, the inter-assay precision was improved to 100%.

All 18 positive specimens were correctly called in a total of 42 trials, yielding 100% CNV detection sensitivity. Three of the 18 positives had a single-exon duplication or deletion, which is known to be challenging to detect by a targeted NGS assay. CNV detection specificity was evaluated from 457 trials of 103 unique specimens. There were 9 false-positive calls from 6 unique specimens including the 4 specimens described in the inter-assay precision study, resulting in 98.0% (448/457) assay specificity. In combination with aCGH confirmation, the CNV detection specificity was 100%

3.4. The First 500 Clinical Specimens. The validated 34-gene panel for variants associated with inherited cancer predisposition was applied to the molecular diagnosis of 500 consecutive, unique de-identified patient specimens. Based on the clinical information submitted, indications for testing included a personal and/or familial history of cancer—most frequently breast, ovarian, or colon. The assay detected a total of 51 pathogenic and 2 likely pathogenic variants in specimens from 49 (9.8%) of the 500 patients. For the first 500 specimens, the panel yielded at VUS rate of 36%. The classification of each variant reflects the classification at the time of reporting. Among the 53 pathogenic/likely pathogenic variants detected, 48 were within exons (26 SNVs and 22 indels), 3 were in splice junctions (3 SNVs), and 2 were CNV variants (a BRCA1 exon 13 duplication, and a PMS2 deletion of exon 7 and 8). The relative distribution of the 53 pathogenic/likely pathogenic variants detected in this study is provided in Table 4. BRCA1/2 were the most frequently mutated genes, with 21 patients harboring 24 pathogenic variants. In addition, 3 patients had pathogenic variants in the Lynch syndrome-associated genes PMS2 (n = 2) and MLH1 (n = 1). The remaining 26 patients had pathogenic/likely pathogenic variants in 9 other genes: monoallelic MUTYH variants in 9 patients; CHEK2 variants in 8; ATM, CDH1, and PALB2 variants in 2 patients each, and BARD1, CDKN2A, RAD51C, and RET variants in 1 patient each. Notably, 4 patients had 2 pathogenic variants each: 3 had pathogenic variants in BRCA1/2, and 1 had pathogenic variants in BRCA2 and MUTYH.

4. Discussion

Various targeted NGS-based multigene inherited cancer panels have been developed by clinical diagnostic laboratories [14, 18–22]. As each laboratory-developed test uses different laboratory procedures and bioinformatics pipelines, rigorous laboratory validation is critical to ensure accurate and reliable results from NGS assays for use in clinical practice [35]. In this study, we demonstrated that the 34-gene cancer predisposition panel achieved 100% analytical sensitivity and specificity for SNVs and small Indels. A well-known challenge for NGS is accurate variant calling in low-complexity and homopolymeric regions. From our inter- and intra-assay precision studies, we identified 4 different positions within homopolymeric context causing discordant variant calls and excluded from reportable range. While one of those positions resulted in 9 false variant calls (31% median variant frequency) out of 270 tested cases, the remaining three resulted in only 1 or 2 false calls (23% median variant frequency). This result suggests the importance of using multiple specimens for precision studies to define reportable range for an NGS assay. A pathogenic splice-site variant, MSH2 c.942 +3A>T, is known to be difficult to detect due to the presence of an adjacent 27 bp polyA sequence. By using a customized GATK Unified Genotyper setting to force calls at each site, we detected 20 cases of MSH2 c.942 +3A>T from 51,129 clinical results of the 34-gene cancer predisposition panel. In comparison, 5 of these cases were not detected with the default Unified Genotyper setting. Therefore, the characteristics of sequence context should be considered for developing an appropriate analysis pipeline.

The presence of pseudogenes can also interfere with variant calling. Accurate molecular testing of the PMS2 3′ region is complicated by the pseudogene PMS2CL, a partial duplication of PMS2 (exon 9, and 11–15), located ~0.7 Mb proximal to PMS2 as a result of an inverted duplication of a 100kb repeat element. To avoid interference from the pseudogene, a PMS2 exon 11–15 sequencing library was prepared from long-range PCR fragments amplified using primers specific to either PMS2 or the PMS2/PMS2CL hybrid allele in the event of a gene conversion [36]. Nonetheless, during development we found a false-negative NGS call for a Sanger sequencing-confirmed variant, c.2466 T>C (rs10000, benign) in PMS2 exon 15. The false-negative call was caused by an adjacent c.*92dupA variant (VUS, pseudogene specific sequence) resulting in preferential sequence alignment to PMS2CL reference sequence. It has been reported that sequence exchange between PMS2 and PMS2CL has led to considerable sequence homogenization, and as a result,
In addition to SNVs and small Indels, CNVs have been implicated as the cause of inherited cancer syndromes [37]. However, accurate CNV detection in targeted NGS data remains challenging. Bias and noise in NGS coverage data, derived from various sources during library preparation, capture, and sequencing, distort the association between copy numbers and read coverages [38, 39]. Despite the excellent sensitivity and specificity of our CNV flagging algorithm, we pseudogene specific variants according to the reference sequence are also found in real gene, and vice versa [36]. The correct call for c.2466 T > C was made upon using the custom reference sequence, which differs from GRCh37 in that PMS2CL sequence (chr7:6,776,750–6,791,250, highly homologous with PMS2 exon 11–15) was replaced with a string of nucleotide T to enhance alignment of the long-range PCR fragment sequence to PMS2 reference sequence.

### Table 4: Pathogenic/likely pathogenic variants detected in the 500 consecutive specimens.

| Gene | No. detected | % | Variant | Type | Classification | No. detected |
|------|--------------|---|---------|------|----------------|--------------|
| BRCA1 | 12       | 23 | c.68_69del (p.Glu23Valfs*17) | DEL | P | 1 |
|       |           |    | c.211A > G (p.Arg71Gly) | SNV | P | 1 |
|       |           |    | c.406dupA (p.Arg136Lysfs*6) | INS | P | 1 |
|       |           |    | c.427G > T (p.Glu143*) | SNV | P | 1 |
|       |           |    | c.1960A > T (p.Lys654*) | SNV | P | 1 |
|       |           |    | c.3193dup (p.Asp1065Glyfs*2) | INS | P | 1 |
|       |           |    | c.4327C > T (p.Arg1443*) | SNV | P | 2 |
|       |           |    | c.5266dup (p.Gln1756Profs*74) | INS | P | 1 |
|       |           |    | c.5353C > T (p.Gln1785*) | SNV | P | 1 |
|       |           |    | c.3598C > T (p.Gln1200*) | SNV | P | 1 |
|       |           |    | Exon 13 Duplication | CNV | P | 1 |
| BRCA2 | 12       | 23 | c.755_758del (p.Asp252Valfs*24) | DEL | P | 1 |
|       |           |    | c.1265del (p.Asn422Ilefs*8) | DEL | P | 1 |
|       |           |    | c.3922G > T (p.Glu1308*) | SNV | P | 1 |
|       |           |    | c.4284dup (p.Gln1429Serfs*9) | INS | P | 1 |
|       |           |    | c.4631dup (p.Asn1544Lysfs*4) | INS | P | 1 |
|       |           |    | c.5290_5291del (p.Ser1764Lysfs*3) | DEL | P | 1 |
| MUTYH | 9        | 17 | c.536A > G (p.Tyr179Cys) | SNV | P | 1 |
|       |           |    | c.1187G > A (p.Gly396Asp) | SNV | P | 6 |
|       |           |    | c.1214C > T (p.Pro405Leu) | SNV | P | 1 |
|       |           |    | c.1477G > T (p.Val493Phe) | SNV | P | 1 |
| CHEK2 | 8        | 15 | c.444+1G > A | SNV | P | 1 |
|       |           |    | c.793–1G > A | SNV | P | 1 |
|       |           |    | c.1100delC (p.Thr367Metfs*15) | DEL | P | 5 |
|       |           |    | c.1169A > C (p.Tyr390Ser) | SNV | LP | 1 |
| ATM   | 2        | 4  | c.7638_7646del (p.Arg2547_Ser2549del) | DEL | P | 1 |
|       |           |    | c.8395_8404del (p.Phe2799Lysfs*4) | DEL | P | 1 |
| PALB2 | 2        | 4  | c.2642_2645dup (p.Cys882Trpfs*3) | INS | P | 1 |
|       |           |    | c.3256C > T (p.Arg1086*) | SNV | P | 1 |
| PMS2  | 2        | 4  | c.809C > G (p.Ser270*) | SNV | P | 1 |
|       |           |    | Exon 7–8 deletion | SNV | CNV | 1 |
| CDH1  | 1        | 2  | c.1565+1G > C | SNV | P | 1 |
| BARD1 | 1        | 2  | c.1690C > T (p.Gln564*) | SNV | P | 1 |
| CDKN2A| 1        | 2  | c.301G > T (p.Gly101Trp) (p16) | SNV | P | 1 |
| MLH1  | 1        | 2  | c.793C > T (p.Arg265Cys) | SNV | P | 1 |
| RAD51C| 1        | 2  | c.773G > A (p.Arg258His) | SNV | LP | 1 |
| RET   | 1        | 2  | c.2410G > A (p.Val804Met) | SNV | P | 1 |
| Total | 53       | 100 |        |      |               | 53 |

P: Pathogenic; LP: likely pathogenic.
observed that the algorithm needed to be supplemented by aCGH to achieve 100% specificity. By using the aCGH supplemented NGS algorithm on 10,068 clinical cases, we detected 57 CNV variants, of which 17 cases were single exon CNV variants (Supplemental Table S2). We extended the CNV flagging algorithm specificity analysis on the 10,068 data set but limited the analysis to only those genes ordered for testing for each specimen. Specificity ranged from 95.5% (34-gene test, n = 1,923) to 100% (13 gene test, n = 122), using the NGS CNV flagging algorithm alone (Supplemental Table S3). Soukupova et al reported that coverage uniformity is an important factor for reliable CNV detection [40]. During assay development we performed multiple rounds of target capture RNA bait design and testing to enhance low-covered region and observed improved coverage uniformity. Further optimization of NGS library preparation procedures, such as using normalized high-quality DNA for library preparation, may improve coverage uniformity and, therefore, CNV specificity. In addition, employing recently described denoising methods based on a signal processing technique may enhance the detection accuracy of our CNV algorithm [38]. Another factor that may confound accurate CNV analysis is a processed pseudogene if its existence is unknown. The unique feature of processed pseudogenes, lacking promoter and intronic sequences, may cause false-positive exonic duplication calls. The presence of an SMAD4 processed pseudogene was first reported in 2015 in a subset of individuals, with a frequency of 0.26% (12/4,672 clinical cases) [41]. A similar frequency (0.25%, 58/23,032 clinical cases, data not shown) was observed from our clinical results. Upon visual inspection using an Integrative Genomics Viewer (IGV), the discontinuous coverage depth pattern on exon/intron boundaries, unique to processed pseudogenes, was readily identified and aCGH confirmation gave a concordant result. In addition, no erroneous splice site variant call was made, and visual inspection with IGV confirmed retention of >98% reference sequence at each intron position within our ROI.

Multigene panel testing can be utilized to identify individuals who are at an increased risk of hereditary cancer. Identification of an inherited risk factor allows patients options decreasing that risk, including increased surveillance, surgery, and/or chemoprevention [18, 24–26]. Targeted testing for at-risk family members can subsequently be performed. If positive, the family member can take steps to prevent cancer or aid in its early detection. Negative results can reassure the family member and prevent unnecessary surveillance or other preventive measures. For women with pathogenic/likely pathogenetic variants in BRCA1/2, some risk-reducing strategies, such as prophylactic surgeries, have demonstrated reduced cancer risk and mortality in some studies [42–44], but not others [45]. Risk-reducing surgery for individuals with BRCA1/2 variants and breast cancer has not yet demonstrated an overall survival benefit. Genetic information can also be used to select the patients most appropriate for targeted therapies. For example, women whose ovarian or breast cancer is associated with pathogenic variants in BRCA1/2 may be treated with poly (ADP-ribose) polymerase (PARP) inhibitors that have been approved for the management of advanced BRCA1/2 mutation-associated ovarian cancer [46–49].

Historically, testing for germline pathogenic or likely pathogenetic variants has been performed sequentially through single-gene or single-syndrome testing. However, a multigene panel approach has a number of advantages over the traditional sequential approach. Previous studies have concluded that multigene panel testing compared with a single-gene testing can cost-effectively improve the identification of at-risk individuals for early health interventions and the outcome of cancer treatment [3, 50].

Recent studies have highlighted that panel testing is able to uncover clinically actionable variants unrelated to the syndrome that the clinician initially suspected [51, 52]. Ricker et al showed that 7.4% (35/475) of patients with deleterious mutations detected with a multigene panel would have had negative results with a gene-by-gene testing approach [21]. Other studies using multigene panels found that over 4% of women at risk of hereditary breast cancer had mutations in genes other than BRCA1/2, including PALB2, CHEK2, and ATM [53, 54]. In our cohort of 49 individuals who had at least one clinically actionable finding, 46 had provided enough clinical criteria to evaluate eligibility for genetic testing based on the National Comprehensive Cancer Network (NCCN) guidelines in effect at the time of testing: 41 met BRCA1/2, 2 met both BRCA1/2 and Lynch criteria, and 3 did not meet either criteria for testing, based on the information provided. Of the individuals that met NCCN criteria for BRCA1/2 testing, 22 (54%) had clinically actionable variants identified in genes other than BRCA1/2 (Supplemental Table S4). Variants were identified in genes causative of hereditary breast cancer, such as ATM, BARD1, CDH1, CHEK2, and PALB2. Because these genes are not associated with a single-gene syndrome, they are not typically interrogated during sequential evaluation. Currently, there are medical management guidelines for these genes, except for BARD1 [25]. However, variants were also identified in genes with no consensus link to hereditary breast cancer, such as MUTYH, PMS2, RAD51C, and RET. The individual found to have the pathogenic RET variant had no reported personal or family history indicative of any of the associated conditions. Interestingly, 8 MUTYH carriers were identified because they were sent for a breast/ovarian indication. In summary, pathogenic and likely pathogenic variants were identified in 8-genes that are not part of single syndrome testing for BRCA-related breast and ovarian cancer syndrome or Lynch syndrome.

Outside of identifying actionable variants in genes incident to the initially suspected syndrome, previous studies have also established that the rate of families carrying more than one actionable variant is higher than what was initially thought, when guidelines recommended cascade testing for only the known familial pathogenic/likely pathogenic variants [55–57]. In our cohort of 49 individuals with actional findings, 5 had verified familial variants. If testing had been restricted to the known familial variants in these cases, the testing strategy would have failed to identify an actionable variant in one of these families, specifically a CHEK2 c.1100delC in a family with a known PMS2 variant. Additionally, of the 500 individuals tested, 4 were identified as having two pathogenic variants (0.8% of the overall cohort, 8% of those who had any actionable finding). Three individuals had a pathogenic variant in
both BRCA1 and BRCA2, one of whom inherited both these mutations from a family member. One individual had a pathogenic variant in BRCA2 and in MUTYH. For this individual, the pathogenic variant in MUTYH would have been missed if testing had been restricted to a single gene/syndrome instead of pursuing panel testing. Currently, individuals with one pathogenic/likely pathogenic variant in MUTYH can consider early and increased surveillance for colon cancer if they have a first degree relative with colon cancer [18]. Moreover, the discovery of the single MUTYH variant also may have a significant impact on this individual’s family members, who may need to consider increased surveillance, based on the presence of one or more clinically significant MUTYH variants. Individuals with biallelic pathogenic/likely pathogenic variants in MUTYH are associated with a lifetime risk of colon cancer of up to 80% [58, 59].

Detection of variants is more common in multigene testing due to the multiplicity of genes tested. Slavin et al summarized the results from 348 commercial multigene panel tests ordered by providers in more than 250 practice settings across the United States. A total of 348 commercial multigene panel tests ordered by providers in 2014 were reviewed and discussed during a weekly case conference. The proportion of clinically actionable results was reported as 17% for panels that included genes of both high and moderate penetrance, and 6.2% for panels that included only genes of high penetrance. When considering all variants identified in this group of patients, the proportion of VUSs was 42%. For 39% of patients, their test results were uninformative. The authors defined uninformative as an individual whose panel results revealed only benign variants and/or likely benign variants, or no variants of any classification detected. In their conclusions, the authors emphasized the importance of pre-test cancer risk assessment, due to the expected higher percentages of positive, nonclinically actionable variants, ambiguous results, and unexpected results with multigene panel testing [60].

One of the ways to reduce the number of individuals with ambiguous test results is to improve open access to variant information identified by laboratories performing genetic tests. Professional societies, including the American College of Medical Genetics and Genomics, advocate for sharing of laboratory and clinical data from individuals who have undergone genomic testing [61, 62]. Data-sharing efforts have been initiated by various organizations, including select commercial laboratories, with the goal of maintaining the privacy of patients and providers [63–65]. We are in support of open access of clinical variants identified through hereditary cancer tests, including the evidence used to determine variant classification. ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/) provides a freely available archive of reports of relationships among medically important variants and phenotypes [34]. Variants identified through clinical testing at our laboratory are routinely submitted to ClinVar.

5. Conclusions

The 34-gene cancer predisposition panel demonstrated satisfactory performance for use in a clinical laboratory, with high sensitivity and specificity for SNVs, small indels, and exon-level CNVs. The panel can provide clinically significant information for cancer risk assessment. Multigene panel testing utilizing NGS may increase detection of pathogenic mutations compared to single-gene testing.

Data Availability

All relevant data are within the paper and its Supplementary Materials files.

Conflicts of Interest

All authors are employees of Quest Diagnostics, and as their compensation, receive salaries and stock options.

Acknowledgments

This work was supported by Quest Diagnostics. The authors thank Jeff Radcliff (Quest Diagnostics) for critical review of the manuscript and the staffs at Molecular Genetics for technical assistance.

Supplementary Materials

Supplemental Table S1. Long-range PCR primers used in this study. Supplemental Table S2. CNV positive cases detected by aCGH supplemented NGS algorithm from 10,068 clinical cases. Supplemental Table S3. NGS CNV flagging algorithm performance evaluation on a larger data set (n = 10,068). Supplemental Table S4. Genetic testing eligibility based on the National Comprehensive Cancer Network (NCCN) guidelines and Pathogenic/likely pathogenic variants identified in the first 500 clinical specimens. (Supplementary Materials)

References

[1] American Cancer Society, Family Cancer Syndromes, 2018.
[2] E. R. Mardis, "A decade’s perspective on DNA sequencing technology," Nature, vol. 470, no. 7333, pp. 198–203, 2011.
[3] Y. Li and A. R. Arellano, L. A. Bare, R. A. Bender, C. M. Strom, J. J. Devlin, "A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer," Value in Health, vol. 20, no. 4, pp. 547–555, 2017.
[4] American Society of Cancer Oncology, "Genetics Toolkit," 2018.
[5] A. Antoniou, P. D. P. Pharoah, S. Narod et al., "Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unsselected for family history: a combined analysis of 22 studies," American Journal of Human Genetics, vol. 72, no. 5, pp. 1117–1130, 2003.
[6] S. Chen and G. Parmigiani, "Meta-analysis of BRCA1 and BRCA2 penetrance," Journal of Clinical Oncology, vol. 25, no. 11, pp. 1329–1333, 2007.
[7] V. Bonadona, B. Bonaiti, S. Olschwang et al., "Bonaiti-Pellié C. for the French Cancer Genetics Network Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 in lynch
syndrome,” The Journal of the American Medical Association, vol. 305, no. 22, pp. 2304–2310, 2011.

[8] P. Möller, T. Seppälä, I. Bernstein et al., “Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database,” Gut, vol. 66, no. 3, pp. 464–472, 2017.

[9] H. F. A. Vasen, A. Stormorken, F. H. Menko et al., “MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families,” Journal of Clinical Oncology, vol. 19, no. 20, pp. 4074–4080, 2001.

[10] C. Loveday, C. Turnbull, E. Ruark et al., “Germline RAD51C mutations confer susceptibility to ovarian cancer,” Nature Genetics, vol. 44, no. 5, pp. 475–476, 2012.

[11] H. Song, E. Dicks, S. I. Ramus et al., “Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population,” Journal of Clinical Oncology, vol. 33, no. 26, pp. 2901–2907, 2015.

[12] Y. H. Choi, M. Cotterchio, G. McKeown-Eyssen et al., “Penetration of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario,” Hereditary Cancer in Clinical Practice, vol. 7 1 4, 2009.

[13] J. G. Dowty, A. K. Win, D. D. Buchanan et al., “Cancer risks for MLH1 and MSH2 mutation carriers,” Human Mutation, vol. 34, no. 3, pp. 490–497, 2013.

[14] D. Ramsoekh, A. Wagner, M. E. van Leerdam et al., “Cancer risk in MLH1, MSH2 and MSH6 mutation carriers: different risk profiles may influence clinical management,” Hereditary Cancer in Clinical Practice, vol. 7 1, p. 17, 2009.

[15] E. Stoffel, B. Mukherjee, V. M. Raymond et al., “Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome,” Gastroenterology, vol. 137, no. 5, pp. 1621–1627, 2009.

[16] S. Syngal, R. E. Brand, J. M. Church, F. M. Giardiello, H. L. Hampel, and R. W. Burt, “AGC clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes,” American Journal of Gastroenterology, vol. 110, no. 2, pp. 223–262, 2015.

[17] R. S. van der Post, L. A. Kiemeneij, M. J. L. Ligtenberg et al., “Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers,” Journal of Medical Genetics, vol. 47, no. 7, pp. 464–470, 2010.

[18] N. C. C. Network, N. C. C. N Clinical Practice Guidelines in Oncology (NCCN Guidelines): Genetic/Familial High-Risk Assessment Colorectal, National Comprehensive Cancer Network, USA, 2018.

[19] F. Kastrinos, “Risk of pancreatic cancer in families with Lynch syndrome,” The Journal of the American Medical Association, vol. 302, no. 16, pp. 1790–1795, 2009.

[20] A. W. Kurian and J. M. Ford, “Multigene panel testing in oncology practice: how should we respond?” The Journal of the American Medical Association Oncology, vol. 1, no. 3, pp. 277–278, 2015.

[21] C. Ricker, J. O. Culver, K. Lowstuter et al., “Increased yield of actionable mutations using multi-gene panels to assess hereditary cancer susceptibility in an ethnically diverse clinical cohort,” Cancer Genetics, vol. 209, no. 4, pp. 130–137, 2016.

[22] M. E. Robson, A. R. Bradbury, B. Arun et al., “American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility,” Journal of Clinical Oncology, vol. 33, no. 31, pp. 3660–3667, 2015.

[23] Committee on Practice Bulletins-Gynecology and Committee on Genetics, Society of Gynecologic Oncology, “ACOG practice bulletin no. 182: Hereditary breast and ovarian cancer syndrome,” Obstetrics and Gynecology, vol. 130, no. 3, pp. e110–e126, 2017.

[24] N. C. C. Network, N. C. C. N Clinical Practice Guidelines in Oncology (NCCN guidelines): Gastric Cancer, 2018.

[25] N. C. C. Network, N. C. C. N Clinical Practice Guidelines in Oncology (NCCN guidelines): Hereditary Breast and Ovarian, 2019.

[26] N. C. C. Network, N. C. C. N Clinical Practice Guidelines in Oncology (NCCN guidelines): prostate cancer, 2018.

[27] L. M. Randall, B. Pothuri, E. M. Swisher et al., “Multi-disciplinary summit on genetics services for women with gynecologic cancers: a society of gynecologic oncology white paper,” Gynecologic Oncology, vol. 146, no. 2, pp. 217–224, 2017.

[28] V. Alliance, V H L A Suggested Active Surveillance Guidelines, 2017.

[29] M. Glendening, H. Hampel, J. Lajeunesse et al., “Long-range PCR facilitates the identification of PMS2-specific mutations,” Human Mutation, vol. 27, no. 5, pp. 490–495, 2006.

[30] C. Alkan, J. M. Kidd, T. Marques-Bonet et al., “Personalized copy number and segmental duplication maps using next-generation sequencing,” Nature Genetics, vol. 41, no. 10, pp. 1061–1067, 2009.

[31] D. Y. Chiang, G. Getz, D. B. Jaffe et al., “High-resolution mapping of copy-number alterations with massively parallel sequencing,” Nature Methods, vol. 6, no. 1, pp. 99–103, 2009.

[32] I. Karbassi, G. A. Maston, A. Love et al., “A standardized DNA variant scoring system for pathogenicity assessments in mendelian disorders,” Human Mutation, vol. 37, no. 1, pp. 127–134, 2016.

[33] S. Richards, N. Aziz, S. Bale et al., “Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology,” Genetics in Medicine, vol. 17, no. 5, pp. 405–424, 2015.

[34] M. J. Landrum, J. M. Lee, G. R. Riley et al., “ClinVar: public archive of relationships among sequence variation and human phenotype,” Nucleic Acids Research, vol. 42, no. D1, pp. D980–985, 2014.

[35] G. Matthijs, E. Souche, M. Alders et al., “Guidelines for diagnostic next-generation sequencing,” European Journal of Human Genetics, vol. 24, no. 1, pp. 2–5, 2016.

[36] C. Ganster, A. Wernstedt, K. Kehler-Sawatzki et al., “Functional PMS2 hybrid alleles containing a pseudogene-specific missense variant trace back to a single ancient intrachromosomal recombination event,” Human Mutation, vol. 31, no. 5, pp. 552–60, 2010.

[37] L. Hu, X. Yao, H. Huang et al., “Clinical significance of germline copy number variation in susceptibility of human diseases,” Journal of Genetics and Genomics, vol. 45, no. 1, pp. 3–12, 2018.

[38] F. Zare, A. Hosny, and S. Nabavi, “Noise cancellation using total variation for copy number variation detection,” BMC Bioinformatics, vol. 19, no. S11, p. 361, 2018.

[39] M. Zhao, Q. Wang, Q. Wang, P. Jia, and Z. Zhao, “Computational tools for copy number variation (CNV) detection using next-
generation sequencing data: features and perspectives," *BMC Bioinformatics*, vol. 14, no. S11, 2013.

[40] J. Soukupova, P. Zemankova, K. Lhotova et al., "Validation of CZEANCA (CZEech CAnceR paNe for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes," *PloS One*, vol. 13, no. 4, p. e0195761, 2018.

[41] A. Millson, T. Lewis, T. Pesaran et al., "Processed pseudogene confounding deletion/duplication assays for SMAD4," *Journal of Molecular Diagnostics*, vol. 17, no. 5, pp. 576–582, 2015.

[42] S. M. Domchek, T. M. Friebel, C. F. Singer et al., "Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality," *The Journal of the American Medical Association*, vol. 304, no. 9, pp. 967–975, 2010.

[43] A. P. Finch, J. Lubinski, P. Molller et al., "Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation," *Journal of Clinical Oncology*, vol. 32, no. 15, pp. 1547–1553, 2014.

[44] K. Metcalfe, S. Gershman, P. Ghadirian et al., "Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis," *British Medical Journal*, vol. 348, p. g.226, 2014.

[45] B. A. M. Heemskerk-Gerritsen, C. Seynaeve, C. J. van Asperen et al., "Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction," *JNCI: Journal of the National Cancer Institute*, vol. 107, no. 5, 2015.

[46] M. W. Audeh, J. Carmichael, R. T. Pensio et al., "Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial," *The Lancet*, vol. 376, no. 9737, pp. 245–251, 2010.

[47] J. Ledermann, P. Harter, C. Gourley et al., "Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial," *The Lancet Oncology*, vol. 15, no. 8, pp. 852–861, 2014.

[48] M. Robson, S. A. Im, E. Senkus et al., "Olaparib for metastatic breast cancer in patients with a germline BRCA mutation," *New England Journal of Medicine*, vol. 377, no. 6, pp. 523–533, 2017.

[49] E. M. Swisher, K. K. Lin, A. M. Oza et al., "Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial," *The Lancet Oncology*, vol. 18, no. 1, pp. 75–87, 2017.

[50] C. J. Gallego, B. H. Shirts, C. S. Bennette et al., "Next-generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a cost-effectiveness analysis," *Journal of Clinical Oncology*, vol. 33, no. 18, pp. 2084–2091, 2015.

[51] D. Cragun, C. Radford, J. S. Dolinsky, M. Caldwell, E. Chao, and T. Pal, "Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory," *Clinical Genetics*, vol. 86, no. 6, pp. 510–520, 2014.

[52] A. W. Kurian, E. E. Hare, M. A. Mills et al., "Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment," *Journal of Clinical Oncology*, vol. 32, no. 19, pp. 2001–2009, 2014.

[53] N. S. Kapoor, L. D. Curcio, C. A. Blakemore et al., "Multigene panel testing detects equal rates of pathogenic BRCA1/2 mutations and has a higher diagnostic yield compared to limited BRCA1/2 analysis alone in patients at risk for hereditary breast cancer," *Annals of Surgical Oncology*, vol. 22, no. 10, pp. 3282–3288, 2015.

[54] N. Tung, S. M. Domchek, Z. Stadler et al., "Counselling framework for moderate-penetrance cancer-susceptibility mutations Nature Reviews," *Clinical Oncology*, vol. 13, no. 9, pp. 581–588, 2016.

[55] H. LaDuca, A. J. Stuenkel, J. S. Dolinsky et al., "Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients," *Genetics in Medicine*, vol. 16, no. 11, pp. 830–837, 2014.

[56] L. R. Susswein, M. L. Marshall, R. Nusbaum et al., "Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing," *Genetics in Medicine*, vol. 18, no. 8, pp. 823–832, 2016.

[57] M. Eliade, J. Skrzypski, A. Baurand et al., "The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: what are the implications for the management of patients and families?" *Oncotarget*, vol. 8, no. 2, pp. 1957–1971, 2017.

[58] A. K. Win, J. G. Dowty, S. P. Cleary et al., "Risk of colorectal cancer for carriers of mutations in mutyh, with and without a family history of cancer," *Gastroenterology*, vol. 146, no. 5, pp. 1208–1211.e5, 2014.

[59] S. Aretz, M. Genuardi, and F. J. Hes, "Clinical utility gene card for: MUTYH-associated polyposis (MAP), autosomal recessive colorectal adenomatous polyposis, multiple colorectal adenomas, multiple andnomatous polyposis (MAP)-2012 update," *European Journal of Human Genetics*, vol. 21, no. 1, 118 pages, 2013.

[60] T. P. Slavin, M. Niell-Swilling, I. Solomon et al., "Clinical application of multigene panels: challenges of next-generation counseling and cancer risk management," *Frontiers in Oncology*, vol. 5, p. 208, 2015.

[61] The Global Alliance for Genomics and Health, "A federated ecosystem for sharing genomic, clinical data," *Science*, vol. 352, no. 6291, pp. 1278–1280, 2016.

[62] ACMG Board of Directors, "Laboratory and clinical genomic data sharing is crucial to improving genetic health care: a position statement of the American College of Medical Genetics and Genomics," *Genetics in Medicine*, vol. 19, no. 7, pp. 721–722, 2017.

[63] ClinGenResource, "About ClinGen," 2019.

[64] The Global Alliance for Genomics and Health, "Enabling responsible genomic data sharing for the benefit of human health," 2017.

[65] K. Lambertson and S. F. Terry, "Free the data," *Genetic Testing and Molecular Biomarkers*, vol. 18, no. 1, pp. 1–2, 2014.